Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Neurological Sciences

• Publication date

  2011-11-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jns.2011.07.021PMID 21824629
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy.

  2011cited by this paper
• Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease

  2011cited by this paper
• Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection

  2011cited by this paper
• Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.

  2010cited by this paper
• Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.

  2010cited by this paper
• Protective effect of systemic L-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25-35) in rat hippocampus.

  2010cited by this paper
• Signaling pathways in mitochondrial dysfunction and aging.

  2010cited by this paper
• A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study

  2010cited by this paper
• Blood levels of kynurenines, interleukin‐23 and soluble human leucocyte antigen‐G at different stages of Huntington’s disease

  2010cited by this paper
• Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease

  2010cited by this paper
• Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.

  2010cited by this paper
• New Therapies for Treating Early Parkinson’s Disease

  2010cited by this paper
• The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.

  2009cited by this paper
• Calcium homeostasis, selective vulnerability and Parkinson's disease.

  2009cited by this paper
• Neuroprotective effects of probenecid in a transgenic animal model of Huntington’s disease

  2009cited by this paper
• [Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].

  2009cited by this paper
• [Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].

  2009cited by this paper
• Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies

  2009cited by this paper
• Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.

  2009cited by this paper
• Implication of NMDA Receptors in the Antidyskinetic Activity of Cabergoline, CI-1041, and Ro 61-8048 in MPTP Monkeys with Levodopa-induced Dyskinesias

  2009cited by this paper
• Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.

  2008cited by this paper
• Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism

  2008cited by this paper
• The Janus-face kynurenic acid

  2008cited by this paper
• Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.

  2008cited by this paper
• Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.

  2008cited by this paper
• Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis

  2007cited by this paper
• ER Stress Signaling and the BCL-2 Family of Proteins: From Adaptation to Irreversible Cellular Damage

  2007cited by this paper
• Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.

  2007cited by this paper
• Kainic acid induces early and transient autophagic stress in mouse hippocampus.

  2007cited by this paper
• A Critical Interaction between NR2B and MAGUK in l-DOPA Induced Dyskinesia

  2006cited by this paper
• Allosteric changes of the NMDA receptor trap diffusible dopamine 1 receptors in spines.

  2006cited by this paper
• Kynurenic acid has a dual action on AMPA receptor responses.

  2006cited by this paper
• ER stress and neurodegenerative diseases

  2006cited by this paper
• Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra

  2006cited by this paper
• Oscillatory pallidal local field potential activity inversely correlates with limb dyskinesias in Parkinson's disease.

  2005cited by this paper
• Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus.

  2005cited by this paper
• Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease.

  2005cited by this paper
• Striatal synaptic plasticity: Implications for motor learning and Parkinson's disease

  2005cited by this paper
• A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease

  2005cited by this paper
• Tryptophan metabolism and oxidative stress in patients with Huntington's disease

  2005cited by this paper
• Kynurenine metabolism in multiple sclerosis

  2005cited by this paper
• Comparative study on the effects of kynurenic acid and glucosamine-kynurenic acid.

  2004cited by this paper
• Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment.

  2004cited by this paper
• Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.

  2004cited by this paper
• Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.

  2003cited by this paper
• Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia

  2003cited by this paper
• Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes.

  2002cited by this paper
• Increased neopterin production and tryptophan degradation in advanced Parkinson's disease

  2002cited by this paper
• Neopterin production, tryptophan degradation, and mental depression--what is the link?

  2002cited by this paper
• Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients.

  2002cited by this paper
• Dopamine D1 Receptor-Dependent Trafficking of Striatal NMDA Glutamate Receptors to the Postsynaptic Membrane

  2001cited by this paper
• The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

  2001cited by this paper
• The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications

  2001cited by this paper
• Persistent changes in striatal gene expression induced by long‐term l‐DOPA treatment in a rat model of Parkinson's disease

  2001cited by this paper
• Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

  2000cited by this paper
• Tryptophan degradation and immune activation in Alzheimer's disease

  2000cited by this paper
• Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine.

  2000cited by this paper
• Kynurenine 3‐Hydroxylase Inhibition in Rats

  2000cited by this paper
• Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus.

  2000cited by this paper
• The glutamate receptor ion channels.

  1999cited by this paper
• Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.

  1999cited by this paper
• Kynurenine metabolism in Alzheimer's disease

  1999cited by this paper
• The Non‐NMDA Glutamate Receptor Antagonists 6‐Cyano‐7‐Nitroquinoxaline‐2,3‐dione and 2,3‐Dihydroxy‐6‐Nitro‐7‐Sulfamoylbenzo(f)quinoxaline, but Not NMDA Antagonists, Block the Intrastriatal Neurotoxic Effect of MPP+

  1999cited by this paper
• Role of High‐Affinity Dopamine Uptake and Impulse Activity in the Appearance of Extracellular Dopamine in Striatum After Administration of Exogenous L‐DOPA

  1999cited by this paper
• Oxidative stress as a mechanism for quinolinic acid‐induced hippocampal damage: protection by melatonin and deprenyl

  1999cited by this paper
• Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeys

  1998cited by this paper
• Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release.

  1998cited by this paper
• Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

  1998cited by this paper
• Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease.

  1997cited by this paper
• Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase.

  1997cited by this paper
• Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.

  1997cited by this paper
• Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid.

  1997cited by this paper
• Prolonged and Extrasynaptic Excitatory Action of Dopamine Mediated by D1 Receptors in the Rat Striatum In Vivo

  1997cited by this paper
• Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases.

  1995cited by this paper
• Biochemistry of Somatodendritic Dopamine Release in Substantia Nigra: An In Vivo Comparison with Striatal Dopamine Release

  1995cited by this paper
• Anatomy and physiology of glutamate in the CNS

  1994cited by this paper
• Synaptic relationships between dopaminergic afferents and cortical or thalamic input in the sensorimotor territory of the striatum in monkey

  1994cited by this paper
• NMDA antagonists partially protect against MPTP induced neurotoxicity in mice

  1993cited by this paper
• Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss.

  1993cited by this paper
• 1‐Methyl‐4‐Phenylpyridinium Produces Excitotoxic Lesions in Rat Striatum as a Result of Impairment of Oxidative Metabolism

  1992cited by this paper
• Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.

  1992cited by this paper
• Kynurenine pathway abnormalities in Parkinson's disease

  1992cited by this paper
• Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism

  1991cited by this paper
• Quinolinic acid is a potent lipid peroxidant in rat brain homogenates

  1991cited by this paper
• Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

  1991cited by this paper
• Protection Against N‐methyl‐D‐aspartate Receptor‐Mediated Neuronal Degeneration In Rat Brain by 7‐chlorokynurenate and 3‐amino‐1‐hydroxypyrrolid‐2‐one, Antagonists at The Allosteric Site for Glycine

  1990cited by this paper
• 7‐Chlorokynurenate Blocks NMDA Receptor‐Mediated Neurotoxicity in Murine Cortical Culture

  1990cited by this paper
• Pathogenesis of dyskinesias in parkinson's disease

  1989cited by this paper
• Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor.

  1988cited by this paper
• Aromatic amino acids and modification of parkinsonism.

  1967cited by this paper

• Kynurenine Pathway Dysregulation in Parkinson’s Disease: Insights for Disease Modulation and Therapy

  2025influential citation
• The ketogenic diet in Parkinson’s disease: a potential therapeutic strategy

  2025cites this paper
• Altered Serotonin Metabolism in Functional Vitamin B12 Deficiency

  2025cites this paper
• Drivers and mechanisms of cognitive decline in chronic kidney disease

  2025cites this paper
• Research Progress of Gut Microbiota on Parkinson’s Disease

  2024cites this paper
• Microbiota, Tryptophan and Aryl Hydrocarbon Receptors as the Target Triad in Parkinson’s Disease—A Narrative Review

  2024cites this paper
• Association between small intestine bacterial overgrowth and psychiatric disorders

  2024cites this paper
• Ageing, Proteostasis, and the Gut: Insights into Neurological Health and Disease.

  2024cites this paper
• Indoleamine 2,3-dioxygenase (IDO1) - Can dendritic cells and monocytes expressing this moonlight enzyme change the phase of Parkinson's Disease?

  2024cites this paper
• Combined targeted and untargeted high-resolution mass spectrometry analyses to investigate metabolic alterations in pompe disease

  2023cites this paper
• Identification of Key Genes and Immunological Features Associated with Copper Metabolism in Parkinson’s Disease by Bioinformatics Analysis

  2023cites this paper
• Neuroimaging genetics approaches to identify new biomarkers for the early diagnosis of autism spectrum disorder

  2023cites this paper
• Considerations for developing a targeted amino acid supplement for people with Parkinson's disease that promotes health while accounting for pathophysiology and medication interference.

  2023cites this paper
• Plasma Metabolic Disturbances in Parkinson’s Disease Patients

  2022cites this paper
• Introduction of benzyloxy pharmacophore into aryl/heteroaryl chalcone motifs as a new class of monoamine oxidase B inhibitors

  2022cites this paper
• New insights on the role of bioactive food derivatives in neurodegeneration and neuroprotection.

  2022cites this paper
• The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases

  2022cites this paper
• Pesticides Exposure-Induced Changes in Brain Metabolome: Implications in the Pathogenesis of Neurodegenerative Disorders

  2022cites this paper
• Metabolomic Biomarkers in Parkinson’s Disease

  2022cites this paper
• Searching for prognostic biomarkers of Parkinson's Disease development in the Spanish EPIC cohort through a multiplatform metabolomics approach

  2021cites this paper
• Imaging of cerebral tryptophan metabolism using 7-[18F]FTrp-PET in a unilateral Parkinsonian rat model

  2021cites this paper
• Metabolic Alterations in a Drosophila Model of Parkinson’s Disease Based on DJ-1 Deficiency

  2021cites this paper
• Kynurenic acid in neurodegenerative disorders—unique neuroprotection or double‐edged sword?

  2021cites this paper
• Pharmacological validation of TDO as a target for Parkinson’s disease

  2021cites this paper
• Changes in the Gut Microbiome and Predicted Functional Metabolic Effects in an Australian Parkinson’s Disease Cohort

  2021cites this paper
• Metabolomics in degenerative brain diseases.

  2021cites this paper
• Prognostic biomarkers of Parkinson’s disease in the Spanish EPIC cohort: a multiplatform metabolomics approach

  2021cites this paper
• A Set of Reliable Samples for the Study of Biomarkers for the Early Diagnosis of Parkinson's Disease

  2021cites this paper
• Prognostic biomarkers of Parkinson’s disease in the Spanish EPIC cohort: a multiplatform metabolomics approach

  2021cites this paper
• “Dialogue” between the Human Microbiome and the Brain

  2021cites this paper
• Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid

  2021cites this paper
• The Role of The Gut Microbiome in Parkinson’s Disease

  2021cites this paper
• Holistic Metabolomic Laboratory-Developed Test (LDT): Development and Use for the Diagnosis of Early-Stage Parkinson’s Disease

  2020cites this paper
• The microbiome-gut-brain axis in acute and chronic brain diseases.

  2019cites this paper
• Study of metabolic disorders associated with BDE-47 exposure in Drosophila model by MS-based metabolomics.

  2019cites this paper
• Neurochemical markers as potential indicators of postmortem tissue quality.

  2018cites this paper
• Carnelian: alignment-free functional binning and abundance estimation of metagenomic reads

  2018cites this paper
• Neurodegeneration and locomotor dysfunction in Drosophila scarlet mutants

  2018cites this paper
• The Influence of Nicotinamide on Health and Disease in the Central Nervous System

  2018cites this paper
• Riboflavin Has Neuroprotective Potential: Focus on Parkinson’s Disease and Migraine

  2017cites this paper
• Substrate and inhibitor specificity of kynurenine monooxygenase from Cytophaga hutchinsonii.

  2017cites this paper
• Monoamine Oxidase B Inhibitors in Parkinson's Disease.

  2017cites this paper
• Alcohol-Enhanced Cu-Mediated Radiofluorination.

  2017cites this paper
• Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis.

  2017cites this paper
• Dityrosine administration induces novel object recognition deficits in young adulthood mice

  2016cites this paper
• Promising therapeutic agents for the treatment of Parkinson’s disease

  2016cites this paper
• First Report of Parkinsonism Associated With Indoximod, an Immune-Modulating Agent

  2016cites this paper
• Expert Opinion on Biological Therapy

  2016cites this paper
• Increased urinary indoxyl sulfate (indican): new insights into gut dysbiosis in Parkinson's disease.

  2015cites this paper
• Systemic L-Kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice

  2015cites this paper
• Chemical profiling with HPLC-FTMS of exogenous and endogenous chemicals susceptible to the administration of chotosan in an animal model of type 2 diabetes-induced dementia.

  2015cites this paper
• Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington’s Disease

  2015cites this paper
• Prediction of Metabolic Gene Biomarkers for Neurodegenerative Disease by an Integrated Network-Based Approach

  2015cites this paper
• Endogenous Kynurenic Acid and Neurotoxicity

  2014cites this paper
• Safinamide for the treatment of Parkinson's disease

  2014cites this paper
• Short-term oral atrazine exposure alters the plasma metabolome of male C57BL/6 mice and disrupts α-linolenate, tryptophan, tyrosine and other major metabolic pathways.

  2014cites this paper
• Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.

  2014cites this paper
• A new hypothesis on preventable neuropsychiatric illness in Africa.

  2014cites this paper
• Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs

  2014cites this paper
• Hypnotic effect of GABA from rice germ and/or tryptophan in a mouse model of pentothal-induced sleep

  2014cites this paper
• Investigating the role of Indoleamine 2,3 dioxygenase in Huntington disease

  2013cites this paper
• 3-Hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system.

  2013cites this paper
• 3‐hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis

  2013cites this paper
• Substituents effects on activity of kynureninase from Homo sapiens and Pseudomonas fluorescens.

  2013cites this paper
• The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.

  2013cites this paper
• Is Ro 61-8048 a potential fast-acting antidepressant?

  2012cites this paper
• Neuroinflammation and Non-motor Symptoms: The Dark Passenger of Parkinson’s Disease?

  2012cites this paper
• Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis

  2012cites this paper
• The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.

  2012cites this paper